Applied DNA Sciences specializes in molecular-based security technologies, particularly through its proprietary Linea™DNA platform. This platform enables the rapid and efficient production of high-fidelity DNA sequences using a cell-free, large-scale PCR-based manufacturing process. The advantages of Linea™DNA include enhanced speed, purity, and scalability, making it a viable alternative to traditional plasmid-based DNA manufacturing. This technology supports the development of next-generation nucleic acid-based therapies, positioning the company at the forefront of therapeutic DNA production.

In addition to its DNA manufacturing capabilities, Applied DNA Sciences offers enterprise-scale diagnostic testing solutions through its clinical laboratory subsidiary, ADCL. This facility is certified for clinical laboratory testing and specializes in DNA detection via PCR, providing genetic testing services that include the TR8™ pharmacogenomics assay. This assay analyzes DNA targets across more than 33 genes, delivering critical genotyping information relevant to various therapeutic areas, including cardiology and oncology. Furthermore, the company’s CertainT® proof point technologies enhance supply chain integrity by enabling the verification of material sources and authenticity, thereby fostering trust and transparency in product claims.

United States

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

Applied DNA Sciences

Company Details